drugset / Trial / NCT00456885
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
Phase 4
Completed
41 enrolled
Beth Israel Deaconess Medical Center
Amylin Pharmaceuticals, LLC. · collabEli Lilly and Company · collab
RandomizedCrossoverDouble-blindTreatment
Summary
This study will look at the effect of exenatide, a drug which has been approved for the treatment of type 2 diabetes, on body weight, appetite and energy expenditure among moderately obese women without diabetes. The study is 35 weeks long and includes 19 outpatient visits. Participants will receive exenatide for 16 weeks and placebo for 16 weeks with a 3 week rest period in between. Neither participants nor investigators will know whether exenatide or placebo is being administered. Participants will be started randomly on either exenatide or placebo. Our hypothesis is that treatment with exenatide will curb appetite and lead to weight loss and may lead to changes in energy expenditure.
Timeline
- Start
- 2007-04
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 10 ug | — |